Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group
Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezoliz...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2022-12, Vol.148 (12), p.3547-3555 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3555 |
|---|---|
| container_issue | 12 |
| container_start_page | 3547 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 148 |
| creator | Gürbüz, Mustafa Kutlu, Yasin Akkuş, Erman Köksoy, Elif Berna Köse, Naziyet Öven, Bala Başak Uluç, Başak Oyan Demiray, Atike Gökçen Erdem, Dilek Demir, Bilgin Turhal, Nazım Serdar Üskent, Necdet Akbaş, Sinem Selçukbiricik, Fatih İnal, Ali Bilici, Ahmet Ölmez, Ömer Fatih Çabuk, Devrim Ünal, Çağlar Hızal, Mutlu Şendur, Mehmet Ali Nahit Korkmaz, Mustafa Karadurmuş, Nuri Ertürk, İsmail Göksu, Sema Sezgin Tatlı, Ali Murat Güven, Deniz Can Kılıçkap, Saadettin Paksoy, Nail Aydıner, Adnan Çınkır, Havva Yeşil Özkul, Özlem Öztürk, Akın Ballı, Sevinç Kemal, Yasemin Erdoğan, Atike Pınar Er, Özlem Yumuk, Perran Fulden Demirkazık, Ahmet |
| description | Purpose
Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC.
Methods
This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis.
Results
A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1–8) and atezolizumab cycle was 7 (1–32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7–7.8), and 11.9 months (95%CI 11–12.7), respectively. The ORR was 61.9%. ECOG-PS (
p
= 0.002) and number of metastatic sites (
p
= 0.001) were associated with PFS and pack-year of smoking (
p
= 0.05), while ECOG-PS (
p
= 0.03) and number of metastatic sites (
p
= 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable.
Conclusion
This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC. |
| doi_str_mv | 10.1007/s00432-022-04087-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2675601657</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2727078338</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-eb6c229a7bd02fae2055fc2add85dba3913b91e379f2e0295ae1ab2fc08746233</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EokPhBVggS2zYBPwzjhN2VUULUqVuytq6ca5nUhJ7sJ0y03fhXeswBSQWLGxf2985vvIh5DVn7zlj-kNibC1FxUQZa9boav-ErPhyxKVUT8mKcc0rJXh9Ql6kdMvKXmnxnJxIVTcta_WK_DzLeB_G4X6eoKM2TN3gsac_hryldotTyFuMsDvQwdNSUjfElKuxQDRHhDyhzzQ4ivuMPg13WKUMG6RpgnGkFss0zn5DLXiL8SMFWlRjMXBIe8iwaBffmzl-G9KWXnsbxrA50MsY5t1L8szBmPDV43pKvl58ujn_XF1dX345P7uqrNQqV9jVVogWdNcz4QAFU8pZAX3fqL4D2XLZtRylbp1AJloFyKETzpZPW9dCylPy7ui7i-H7jCmbaUhL8-AxzMmIWqua8Vrpgr79B70Nc_SlOyO00Ew3UjaFEkfKxpBSRGd2cZggHgxnZgnPHMMzJTzzKzyzL6I3j9ZzN2H_R_I7rQLII5DKld9g_Pv2f2wfAGFUqA4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2727078338</pqid></control><display><type>article</type><title>Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group</title><source>SpringerNature Journals</source><creator>Gürbüz, Mustafa ; Kutlu, Yasin ; Akkuş, Erman ; Köksoy, Elif Berna ; Köse, Naziyet ; Öven, Bala Başak ; Uluç, Başak Oyan ; Demiray, Atike Gökçen ; Erdem, Dilek ; Demir, Bilgin ; Turhal, Nazım Serdar ; Üskent, Necdet ; Akbaş, Sinem ; Selçukbiricik, Fatih ; İnal, Ali ; Bilici, Ahmet ; Ölmez, Ömer Fatih ; Çabuk, Devrim ; Ünal, Çağlar ; Hızal, Mutlu ; Şendur, Mehmet Ali Nahit ; Korkmaz, Mustafa ; Karadurmuş, Nuri ; Ertürk, İsmail ; Göksu, Sema Sezgin ; Tatlı, Ali Murat ; Güven, Deniz Can ; Kılıçkap, Saadettin ; Paksoy, Nail ; Aydıner, Adnan ; Çınkır, Havva Yeşil ; Özkul, Özlem ; Öztürk, Akın ; Ballı, Sevinç ; Kemal, Yasemin ; Erdoğan, Atike Pınar ; Er, Özlem ; Yumuk, Perran Fulden ; Demirkazık, Ahmet</creator><creatorcontrib>Gürbüz, Mustafa ; Kutlu, Yasin ; Akkuş, Erman ; Köksoy, Elif Berna ; Köse, Naziyet ; Öven, Bala Başak ; Uluç, Başak Oyan ; Demiray, Atike Gökçen ; Erdem, Dilek ; Demir, Bilgin ; Turhal, Nazım Serdar ; Üskent, Necdet ; Akbaş, Sinem ; Selçukbiricik, Fatih ; İnal, Ali ; Bilici, Ahmet ; Ölmez, Ömer Fatih ; Çabuk, Devrim ; Ünal, Çağlar ; Hızal, Mutlu ; Şendur, Mehmet Ali Nahit ; Korkmaz, Mustafa ; Karadurmuş, Nuri ; Ertürk, İsmail ; Göksu, Sema Sezgin ; Tatlı, Ali Murat ; Güven, Deniz Can ; Kılıçkap, Saadettin ; Paksoy, Nail ; Aydıner, Adnan ; Çınkır, Havva Yeşil ; Özkul, Özlem ; Öztürk, Akın ; Ballı, Sevinç ; Kemal, Yasemin ; Erdoğan, Atike Pınar ; Er, Özlem ; Yumuk, Perran Fulden ; Demirkazık, Ahmet</creatorcontrib><description>Purpose
Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC.
Methods
This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis.
Results
A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1–8) and atezolizumab cycle was 7 (1–32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7–7.8), and 11.9 months (95%CI 11–12.7), respectively. The ORR was 61.9%. ECOG-PS (
p
= 0.002) and number of metastatic sites (
p
= 0.001) were associated with PFS and pack-year of smoking (
p
= 0.05), while ECOG-PS (
p
= 0.03) and number of metastatic sites (
p
= 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable.
Conclusion
This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-022-04087-x</identifier><identifier>PMID: 35689097</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Cancer Research ; Chemotherapy ; Hematology ; Immunotherapy ; Internal Medicine ; Lung cancer ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Monoclonal antibodies ; Multivariate analysis ; Oncology ; Original Article – Clinical Oncology ; Patients ; Small cell lung carcinoma ; Targeted cancer therapy</subject><ispartof>Journal of cancer research and clinical oncology, 2022-12, Vol.148 (12), p.3547-3555</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-eb6c229a7bd02fae2055fc2add85dba3913b91e379f2e0295ae1ab2fc08746233</citedby><cites>FETCH-LOGICAL-c375t-eb6c229a7bd02fae2055fc2add85dba3913b91e379f2e0295ae1ab2fc08746233</cites><orcidid>0000-0001-7680-4142</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-022-04087-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-022-04087-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,782,786,27933,27934,41497,42566,51328</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35689097$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gürbüz, Mustafa</creatorcontrib><creatorcontrib>Kutlu, Yasin</creatorcontrib><creatorcontrib>Akkuş, Erman</creatorcontrib><creatorcontrib>Köksoy, Elif Berna</creatorcontrib><creatorcontrib>Köse, Naziyet</creatorcontrib><creatorcontrib>Öven, Bala Başak</creatorcontrib><creatorcontrib>Uluç, Başak Oyan</creatorcontrib><creatorcontrib>Demiray, Atike Gökçen</creatorcontrib><creatorcontrib>Erdem, Dilek</creatorcontrib><creatorcontrib>Demir, Bilgin</creatorcontrib><creatorcontrib>Turhal, Nazım Serdar</creatorcontrib><creatorcontrib>Üskent, Necdet</creatorcontrib><creatorcontrib>Akbaş, Sinem</creatorcontrib><creatorcontrib>Selçukbiricik, Fatih</creatorcontrib><creatorcontrib>İnal, Ali</creatorcontrib><creatorcontrib>Bilici, Ahmet</creatorcontrib><creatorcontrib>Ölmez, Ömer Fatih</creatorcontrib><creatorcontrib>Çabuk, Devrim</creatorcontrib><creatorcontrib>Ünal, Çağlar</creatorcontrib><creatorcontrib>Hızal, Mutlu</creatorcontrib><creatorcontrib>Şendur, Mehmet Ali Nahit</creatorcontrib><creatorcontrib>Korkmaz, Mustafa</creatorcontrib><creatorcontrib>Karadurmuş, Nuri</creatorcontrib><creatorcontrib>Ertürk, İsmail</creatorcontrib><creatorcontrib>Göksu, Sema Sezgin</creatorcontrib><creatorcontrib>Tatlı, Ali Murat</creatorcontrib><creatorcontrib>Güven, Deniz Can</creatorcontrib><creatorcontrib>Kılıçkap, Saadettin</creatorcontrib><creatorcontrib>Paksoy, Nail</creatorcontrib><creatorcontrib>Aydıner, Adnan</creatorcontrib><creatorcontrib>Çınkır, Havva Yeşil</creatorcontrib><creatorcontrib>Özkul, Özlem</creatorcontrib><creatorcontrib>Öztürk, Akın</creatorcontrib><creatorcontrib>Ballı, Sevinç</creatorcontrib><creatorcontrib>Kemal, Yasemin</creatorcontrib><creatorcontrib>Erdoğan, Atike Pınar</creatorcontrib><creatorcontrib>Er, Özlem</creatorcontrib><creatorcontrib>Yumuk, Perran Fulden</creatorcontrib><creatorcontrib>Demirkazık, Ahmet</creatorcontrib><title>Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose
Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC.
Methods
This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis.
Results
A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1–8) and atezolizumab cycle was 7 (1–32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7–7.8), and 11.9 months (95%CI 11–12.7), respectively. The ORR was 61.9%. ECOG-PS (
p
= 0.002) and number of metastatic sites (
p
= 0.001) were associated with PFS and pack-year of smoking (
p
= 0.05), while ECOG-PS (
p
= 0.03) and number of metastatic sites (
p
= 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable.
Conclusion
This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC.</description><subject>Cancer Research</subject><subject>Chemotherapy</subject><subject>Hematology</subject><subject>Immunotherapy</subject><subject>Internal Medicine</subject><subject>Lung cancer</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Multivariate analysis</subject><subject>Oncology</subject><subject>Original Article – Clinical Oncology</subject><subject>Patients</subject><subject>Small cell lung carcinoma</subject><subject>Targeted cancer therapy</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kc1u1DAUhS0EokPhBVggS2zYBPwzjhN2VUULUqVuytq6ca5nUhJ7sJ0y03fhXeswBSQWLGxf2985vvIh5DVn7zlj-kNibC1FxUQZa9boav-ErPhyxKVUT8mKcc0rJXh9Ql6kdMvKXmnxnJxIVTcta_WK_DzLeB_G4X6eoKM2TN3gsac_hryldotTyFuMsDvQwdNSUjfElKuxQDRHhDyhzzQ4ivuMPg13WKUMG6RpgnGkFss0zn5DLXiL8SMFWlRjMXBIe8iwaBffmzl-G9KWXnsbxrA50MsY5t1L8szBmPDV43pKvl58ujn_XF1dX345P7uqrNQqV9jVVogWdNcz4QAFU8pZAX3fqL4D2XLZtRylbp1AJloFyKETzpZPW9dCylPy7ui7i-H7jCmbaUhL8-AxzMmIWqua8Vrpgr79B70Nc_SlOyO00Ew3UjaFEkfKxpBSRGd2cZggHgxnZgnPHMMzJTzzKzyzL6I3j9ZzN2H_R_I7rQLII5DKld9g_Pv2f2wfAGFUqA4</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Gürbüz, Mustafa</creator><creator>Kutlu, Yasin</creator><creator>Akkuş, Erman</creator><creator>Köksoy, Elif Berna</creator><creator>Köse, Naziyet</creator><creator>Öven, Bala Başak</creator><creator>Uluç, Başak Oyan</creator><creator>Demiray, Atike Gökçen</creator><creator>Erdem, Dilek</creator><creator>Demir, Bilgin</creator><creator>Turhal, Nazım Serdar</creator><creator>Üskent, Necdet</creator><creator>Akbaş, Sinem</creator><creator>Selçukbiricik, Fatih</creator><creator>İnal, Ali</creator><creator>Bilici, Ahmet</creator><creator>Ölmez, Ömer Fatih</creator><creator>Çabuk, Devrim</creator><creator>Ünal, Çağlar</creator><creator>Hızal, Mutlu</creator><creator>Şendur, Mehmet Ali Nahit</creator><creator>Korkmaz, Mustafa</creator><creator>Karadurmuş, Nuri</creator><creator>Ertürk, İsmail</creator><creator>Göksu, Sema Sezgin</creator><creator>Tatlı, Ali Murat</creator><creator>Güven, Deniz Can</creator><creator>Kılıçkap, Saadettin</creator><creator>Paksoy, Nail</creator><creator>Aydıner, Adnan</creator><creator>Çınkır, Havva Yeşil</creator><creator>Özkul, Özlem</creator><creator>Öztürk, Akın</creator><creator>Ballı, Sevinç</creator><creator>Kemal, Yasemin</creator><creator>Erdoğan, Atike Pınar</creator><creator>Er, Özlem</creator><creator>Yumuk, Perran Fulden</creator><creator>Demirkazık, Ahmet</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7680-4142</orcidid></search><sort><creationdate>20221201</creationdate><title>Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group</title><author>Gürbüz, Mustafa ; Kutlu, Yasin ; Akkuş, Erman ; Köksoy, Elif Berna ; Köse, Naziyet ; Öven, Bala Başak ; Uluç, Başak Oyan ; Demiray, Atike Gökçen ; Erdem, Dilek ; Demir, Bilgin ; Turhal, Nazım Serdar ; Üskent, Necdet ; Akbaş, Sinem ; Selçukbiricik, Fatih ; İnal, Ali ; Bilici, Ahmet ; Ölmez, Ömer Fatih ; Çabuk, Devrim ; Ünal, Çağlar ; Hızal, Mutlu ; Şendur, Mehmet Ali Nahit ; Korkmaz, Mustafa ; Karadurmuş, Nuri ; Ertürk, İsmail ; Göksu, Sema Sezgin ; Tatlı, Ali Murat ; Güven, Deniz Can ; Kılıçkap, Saadettin ; Paksoy, Nail ; Aydıner, Adnan ; Çınkır, Havva Yeşil ; Özkul, Özlem ; Öztürk, Akın ; Ballı, Sevinç ; Kemal, Yasemin ; Erdoğan, Atike Pınar ; Er, Özlem ; Yumuk, Perran Fulden ; Demirkazık, Ahmet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-eb6c229a7bd02fae2055fc2add85dba3913b91e379f2e0295ae1ab2fc08746233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cancer Research</topic><topic>Chemotherapy</topic><topic>Hematology</topic><topic>Immunotherapy</topic><topic>Internal Medicine</topic><topic>Lung cancer</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Multivariate analysis</topic><topic>Oncology</topic><topic>Original Article – Clinical Oncology</topic><topic>Patients</topic><topic>Small cell lung carcinoma</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gürbüz, Mustafa</creatorcontrib><creatorcontrib>Kutlu, Yasin</creatorcontrib><creatorcontrib>Akkuş, Erman</creatorcontrib><creatorcontrib>Köksoy, Elif Berna</creatorcontrib><creatorcontrib>Köse, Naziyet</creatorcontrib><creatorcontrib>Öven, Bala Başak</creatorcontrib><creatorcontrib>Uluç, Başak Oyan</creatorcontrib><creatorcontrib>Demiray, Atike Gökçen</creatorcontrib><creatorcontrib>Erdem, Dilek</creatorcontrib><creatorcontrib>Demir, Bilgin</creatorcontrib><creatorcontrib>Turhal, Nazım Serdar</creatorcontrib><creatorcontrib>Üskent, Necdet</creatorcontrib><creatorcontrib>Akbaş, Sinem</creatorcontrib><creatorcontrib>Selçukbiricik, Fatih</creatorcontrib><creatorcontrib>İnal, Ali</creatorcontrib><creatorcontrib>Bilici, Ahmet</creatorcontrib><creatorcontrib>Ölmez, Ömer Fatih</creatorcontrib><creatorcontrib>Çabuk, Devrim</creatorcontrib><creatorcontrib>Ünal, Çağlar</creatorcontrib><creatorcontrib>Hızal, Mutlu</creatorcontrib><creatorcontrib>Şendur, Mehmet Ali Nahit</creatorcontrib><creatorcontrib>Korkmaz, Mustafa</creatorcontrib><creatorcontrib>Karadurmuş, Nuri</creatorcontrib><creatorcontrib>Ertürk, İsmail</creatorcontrib><creatorcontrib>Göksu, Sema Sezgin</creatorcontrib><creatorcontrib>Tatlı, Ali Murat</creatorcontrib><creatorcontrib>Güven, Deniz Can</creatorcontrib><creatorcontrib>Kılıçkap, Saadettin</creatorcontrib><creatorcontrib>Paksoy, Nail</creatorcontrib><creatorcontrib>Aydıner, Adnan</creatorcontrib><creatorcontrib>Çınkır, Havva Yeşil</creatorcontrib><creatorcontrib>Özkul, Özlem</creatorcontrib><creatorcontrib>Öztürk, Akın</creatorcontrib><creatorcontrib>Ballı, Sevinç</creatorcontrib><creatorcontrib>Kemal, Yasemin</creatorcontrib><creatorcontrib>Erdoğan, Atike Pınar</creatorcontrib><creatorcontrib>Er, Özlem</creatorcontrib><creatorcontrib>Yumuk, Perran Fulden</creatorcontrib><creatorcontrib>Demirkazık, Ahmet</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gürbüz, Mustafa</au><au>Kutlu, Yasin</au><au>Akkuş, Erman</au><au>Köksoy, Elif Berna</au><au>Köse, Naziyet</au><au>Öven, Bala Başak</au><au>Uluç, Başak Oyan</au><au>Demiray, Atike Gökçen</au><au>Erdem, Dilek</au><au>Demir, Bilgin</au><au>Turhal, Nazım Serdar</au><au>Üskent, Necdet</au><au>Akbaş, Sinem</au><au>Selçukbiricik, Fatih</au><au>İnal, Ali</au><au>Bilici, Ahmet</au><au>Ölmez, Ömer Fatih</au><au>Çabuk, Devrim</au><au>Ünal, Çağlar</au><au>Hızal, Mutlu</au><au>Şendur, Mehmet Ali Nahit</au><au>Korkmaz, Mustafa</au><au>Karadurmuş, Nuri</au><au>Ertürk, İsmail</au><au>Göksu, Sema Sezgin</au><au>Tatlı, Ali Murat</au><au>Güven, Deniz Can</au><au>Kılıçkap, Saadettin</au><au>Paksoy, Nail</au><au>Aydıner, Adnan</au><au>Çınkır, Havva Yeşil</au><au>Özkul, Özlem</au><au>Öztürk, Akın</au><au>Ballı, Sevinç</au><au>Kemal, Yasemin</au><au>Erdoğan, Atike Pınar</au><au>Er, Özlem</au><au>Yumuk, Perran Fulden</au><au>Demirkazık, Ahmet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>148</volume><issue>12</issue><spage>3547</spage><epage>3555</epage><pages>3547-3555</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Purpose
Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC.
Methods
This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis.
Results
A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1–8) and atezolizumab cycle was 7 (1–32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7–7.8), and 11.9 months (95%CI 11–12.7), respectively. The ORR was 61.9%. ECOG-PS (
p
= 0.002) and number of metastatic sites (
p
= 0.001) were associated with PFS and pack-year of smoking (
p
= 0.05), while ECOG-PS (
p
= 0.03) and number of metastatic sites (
p
= 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable.
Conclusion
This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>35689097</pmid><doi>10.1007/s00432-022-04087-x</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7680-4142</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2022-12, Vol.148 (12), p.3547-3555 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2675601657 |
| source | SpringerNature Journals |
| subjects | Cancer Research Chemotherapy Hematology Immunotherapy Internal Medicine Lung cancer Medicine Medicine & Public Health Metastases Metastasis Monoclonal antibodies Multivariate analysis Oncology Original Article – Clinical Oncology Patients Small cell lung carcinoma Targeted cancer therapy |
| title | Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-30T02%3A31%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atezolizumab%20combined%20with%20chemotherapy%20in%20the%20first-line%20treatment%20of%20extensive-stage%20small%20cell%20lung%20cancer:%20a%20real-life%20data%20of%20the%20Turkish%20Oncology%20Group&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=G%C3%BCrb%C3%BCz,%20Mustafa&rft.date=2022-12-01&rft.volume=148&rft.issue=12&rft.spage=3547&rft.epage=3555&rft.pages=3547-3555&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-022-04087-x&rft_dat=%3Cproquest_cross%3E2727078338%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2727078338&rft_id=info:pmid/35689097&rfr_iscdi=true |